CoChat

The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma

Davies, Faith E., Forsyth, Peter D., Rawstron, Andrew C., Owen, Roger G., Pratt, Guy, Evans, Paul A. S., Richards, Stephen J., Drayson, Mark, Smith, Graeme M., Selby, Peter J., Child, J. Anthony, Morgan, Gareth J. · 2001 · British Journal of Haematology
Cited by 110

The DOI matches its Crossref record.

Abstract

Initial studies with high‐dose therapy (HDT) in myeloma suggest some beneficial effects of attaining a complete response (CR); however, the effect on survival is difficult to assess owing to inconsistencies in the definition of response between studies. We have analysed 96 newly diagnosed patients aged less than 65 years who received HDT and assessed the effect of response on survival using electrophoresis, immunofixation and fluorescent IgH polymerase chain reaction (PCR) to define CR. Patients received induction chemotherapy with C‐VAMP (adriamycin, vincristine, methylprednisolone, cyclophosphamide) followed by melphalan 200 mg/m 2 and reinfusion of peripheral blood stem cells. There was a high response to C‐VAMP [CR = 24%, partial response (PR) = 64%], with all but one patient improving the depth of response after HDT (CR = 69%, PR = 31%). The progression‐free survival (PFS) and overall survival (OS) were excellent at a median of 46·4 months and 72+ months. There was a trend towards an improved PFS in patients with an immunofixation‐negative CR compared with patients with a PR (49·4 months, 41·14 months; P = 0·26). This was not evident when electrophoresis was used to define CR. The method used to define CR did not impact on the overall survival and fluorescent IgH PCR failed to add any additional prognostic information. This study supports the widespread use of the European Bone Marrow Transplantation group (EBMT) response criteria and suggests that immunofixation should be performed on all patients who become electrophoresis negative.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2001.02530.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 110

Metadata

Authors
Davies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P. A. S., Richards, S. J., Drayson, M., Smith, G. M., Selby, P. J., Child, J. A., & Morgan, G. J.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2001-03
Volume
112
Issue
3
Pages
814-819
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1990708897
Cited by
110
References
0
FWCI
4.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma. https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.02530.x
The paper
Davies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P. A. S., Richards, S. J., Drayson, M., Smith, G. M., Selby, P. J., Child, J. A., & Morgan, G. J. (2001). The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.02530.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.